Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSOT07)

Drug Name
CP-83101 Drug Info
Synonyms
AC1O5PZP; SCHEMBL1660808; SCHEMBL1660809; CP-83101; 3,5-Dihydroxy-9,9-diphenyl-6,8-nonadienoate; methyl (3R,5S,6E)-3,5-dihydroxy-9,9-diphenylnona-6,8-dienoate; 6,8-Nonadienoic acid, 3,5-dihydroxy-9,9-diphenyl-, methyl ester, (R*,S*-(E))-(+-)-
Indication
Disease Entry ICD 11 Status REF
Arteriosclerosis BD40 Terminated [1]
Cross-matching ID
PubChem CID
6438614
CAS Number
CAS 130746-82-6
TTD Drug ID
DMSOT07

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting HMG-CoA reductase (HMGCR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pravastatin DM6A0X7 Adult acute monocytic leukemia Approved [3]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [4]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [5]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [6]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [7]
Fluvastatin DM4MDJY Arteriosclerosis BD40 Approved [4]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [8]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [4]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [9]
Teriflunomide DMQ2FKJ Hyperlipidaemia 5C80 Approved [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000245)
2 Efficacy, tissue distribution and biliary excretion of methyl (3R*,5S*)-(E)-3,5-dihydroxy-9,9-diphenyl-6,8-nonadienoate (CP-83101), a hepatoselective inhibitor of HMG-CoA reductase activity in the rat. Biochem Pharmacol. 1990 Sep 15;40(6):1281-93.
3 A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9.
4 Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
5 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
6 Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203.
7 New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.
8 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
9 Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.